These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20713999)

  • 1. Chronic hepatitis C treatment in näive patients.
    Daruich J
    Ann Hepatol; 2010; 9 Suppl():65-71. PubMed ID: 20713999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C].
    Wang M; Zheng W; Zhang H; Li Z; Jiang D; Liu Y; Zhou R; Li XG; Zhang Y; Zhang Z; Wu S; Zhang Y; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):255-9. PubMed ID: 25173222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
    Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
    Huang YX; Chen XY; Ma LN; Yin JM; Ren S; Guo DD; Zheng YH
    Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):216-20. PubMed ID: 22475143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.
    Sporea I; Sirli R; Curescu M; Gheorghe L; Popescu A; Bota S; Iacob S
    J Gastrointestin Liver Dis; 2010 Sep; 19(3):261-4. PubMed ID: 20922189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
    Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
    Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination.
    Ohara T; Oteki T; Suzuki T; Suzuki M; Matsuzaki Y
    Hepatogastroenterology; 2011; 58(105):133-6. PubMed ID: 21510300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic hepatitis C in southern Taiwan.
    Chuang WL; Yu ML; Dai CY; Chang WY
    Intervirology; 2006; 49(1-2):99-106. PubMed ID: 16166797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
    Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
    Cheong HR; Woo HY; Heo J; Yoon KT; Kim DU; Kim GH; Kang DH; Song GA; Cho M
    Korean J Hepatol; 2010 Mar; 16(1):38-48. PubMed ID: 20375641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Peg-IFNa-2a/RBV antiviral efficacy in cirrhotic hepatitis C patients after splenectomy or partial splenic embolization].
    Xie YM; Li B; Ma L; Pan L; Wei X; Peng XJ; Hao CQ; Zhang Y; Bai XF; Kang WZ; Jia ZS
    Zhonghua Gan Zang Bing Za Zhi; 2012 Feb; 20(2):112-5. PubMed ID: 22464782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C.
    Markova AA; Mihm U; Schlaphoff V; Lunemann S; Filmann N; Bremer B; Berg T; Sarrazin C; Zeuzem S; Manns MP; Cornberg M; Herrmann E; Wedemeyer H
    PLoS One; 2014; 9(4):e94512. PubMed ID: 24751903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.